164 related articles for article (PubMed ID: 24879326)
1. Intraorbital injection of Rituximab in idiopathic orbital inflammatory syndrome: case reports.
Savino G; Battendieri R; Siniscalco A; Mandarà E; Mulè A; Petrone G; Traina S; Riso M
Rheumatol Int; 2015 Jan; 35(1):183-8. PubMed ID: 24879326
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases.
Wu A; Andrew NH; Tsirbas A; Tan P; Gajdatsy A; Selva D
Eye (Lond); 2015 Jan; 29(1):122-8. PubMed ID: 25341435
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.
Suhler EB; Lim LL; Beardsley RM; Giles TR; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Smith JR; Rosenbaum JT
JAMA Ophthalmol; 2014 May; 132(5):572-8. PubMed ID: 24652467
[TBL] [Abstract][Full Text] [Related]
4. [Idiopathic orbital inflammatory syndrome: Report of 24 cases].
Khochtali S; Zayani M; Ksiaa I; Ben Meriem I; Zaouali S; Jelliti B; Khairallah M
J Fr Ophtalmol; 2018 Apr; 41(4):333-342. PubMed ID: 29685738
[TBL] [Abstract][Full Text] [Related]
5. Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.
Savino G; Mandarà E; Gari M; Battendieri R; Corsello SM; Pontecorvi A
Endocrine; 2015 Feb; 48(1):241-7. PubMed ID: 24880619
[TBL] [Abstract][Full Text] [Related]
6. Complete resolution of idiopathic sclerosing orbital inflammation after treatment with rituximab.
Abell RG; Patrick A; Rooney KG; McKelvie PA; McNab AA
Ocul Immunol Inflamm; 2015 Apr; 23(2):176-9. PubMed ID: 24354478
[No Abstract] [Full Text] [Related]
7. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients.
Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH
Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556
[TBL] [Abstract][Full Text] [Related]
8. Intralesional corticosteroid injections as treatment for non-infectious orbital inflammation.
Reggie S; Neimkin M; Holds J
Orbit; 2018 Feb; 37(1):41-47. PubMed ID: 28872378
[TBL] [Abstract][Full Text] [Related]
9. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis.
Wallwork R; Wallace Z; Perugino C; Sharma A; Stone JH
Medicine (Baltimore); 2018 Oct; 97(42):e12631. PubMed ID: 30334947
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
11. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
Su GX; Wu FQ; Wang F; Zhou ZX; Huang XL; Lu J
Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
[TBL] [Abstract][Full Text] [Related]
12. Intraorbital injection of triamcinolone acetonide in patients with idiopathic orbital inflammation.
Leibovitch I; Prabhakaran VC; Davis G; Selva D
Arch Ophthalmol; 2007 Dec; 125(12):1647-51. PubMed ID: 18071116
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
[TBL] [Abstract][Full Text] [Related]
14. High-Dose Rituximab Ineffective for Focal Segmental Glomerulosclerosis: A Long-Term Observation Study.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Barreca A; Fenoglio R; Baldovino S; Menegatti E
Am J Nephrol; 2017; 46(2):108-113. PubMed ID: 28700988
[TBL] [Abstract][Full Text] [Related]
15. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
16. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.
Cartin-Ceba R; Keogh KA; Specks U; Sethi S; Fervenza FC
Nephrol Dial Transplant; 2011 Sep; 26(9):2865-71. PubMed ID: 21325353
[TBL] [Abstract][Full Text] [Related]
17. IgG4-related systemic disease as a cause of "idiopathic" orbital inflammation, including orbital myositis, and trigeminal nerve involvement.
Wallace ZS; Khosroshahi A; Jakobiec FA; Deshpande V; Hatton MP; Ritter J; Ferry JA; Stone JH
Surv Ophthalmol; 2012; 57(1):26-33. PubMed ID: 22018678
[TBL] [Abstract][Full Text] [Related]
18. Clinical and histopathological findings of patients with orbital granulomatosis with polyangiitis cases refractory to rituximab.
Starr MR; Garrity JA; Tooley AA; Salomão DR
Can J Ophthalmol; 2019 Dec; 54(6):682-687. PubMed ID: 31836100
[TBL] [Abstract][Full Text] [Related]
19. Effect of different rituximab regimens on B cell depletion and time to relapse in children with steroid-dependent nephrotic syndrome.
Hogan J; Dossier C; Kwon T; Macher MA; Maisin A; Couderc A; Niel O; Baudouin V; Deschênes G
Pediatr Nephrol; 2019 Feb; 34(2):253-259. PubMed ID: 30109447
[TBL] [Abstract][Full Text] [Related]
20. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
Kerl K; Prins C; Saurat JH; French LE
Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
